3681.Hk
3681.HK is a pharmaceutical company engaged in the development and commercialization of biotechnology-based products, primarily within the healthcare sector.
Business. 3681.HK is a pharmaceutical company engaged in the development and commercialization of biotechnology-based products, primarily within the healthcare sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
3681.HK is a pharmaceutical company engaged in the development and commercialization of biotechnology-based products, primarily within the healthcare sector.
The company's capital structure is characterized by a debt-to-equity ratio of 0.67, indicating a moderate reliance on debt financing. It holds CNY 322.7 million in cash and equivalents, but this is offset by CNY 338.5 million in long-term debt, resulting in a net cash position that is negative. The current ratio of 1.91 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the liquidity risk remains medium due to the net cash shortfall.
Profitability metrics are weak, with a return on equity of -20.67% and a return on assets of -11.56%. These figures are significantly below the industry norms for pharmaceutical companies, which typically exhibit positive returns. The company reported a net loss of CNY 104.99 million and an operating loss of CNY 99.46 million, indicating ongoing operational challenges.
The company's revenue is not disclosed in the latest financial data, and there is no segment or geographic breakdown provided. This lack of transparency makes it difficult to assess the concentration of revenue across different product lines or regions. However, the absence of segment data suggests the company may be in an early stage of development or may not have diversified its operations.
Looking ahead, the company is expected to continue facing financial pressures. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability. The absence of positive growth indicators and the continued net losses suggest that the company is in a challenging phase of its development.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative, which could limit its ability to fund operations without external financing. However, the dilution risk is low, as there is no indication of imminent share issuance or other dilutive events.
Recent events and filings do not provide additional insight into the company's operations or strategic direction. The lack of recent disclosures or transcripts suggests that the company may not be actively engaging with investors or providing regular updates on its progress.
- The company is currently unprofitable, with a return on equity of -20.67% and a return on assets of -11.56%.
- It has a moderate debt-to-equity ratio of 0.67, but its net cash position is negative due to long-term debt exceeding cash reserves.
- The company's financial performance is below industry norms, and there is no indication of improvement in the near term.
- There is a lack of segment and geographic revenue data, making it difficult to assess diversification and exposure.
- The liquidity risk is medium, and the dilution risk is low, but the company may need to seek additional financing to support operations.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- 3681.HK Market data — financials · 2026-05-26